FDA Clears NMP22 BladderChek for Monitoring of Bladder Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 9
Volume 11
Issue 9

NEWTON, Mass-Matritech Inc. has received clearance from the US Food and Drug Administration to market NMP22 BladderChek for monitoring patients with a history of bladder cancer.

 NEWTON, Mass—Matritech Inc. has received clearance from the US Food and Drug Administration to market NMP22 BladderChek for monitoring patients with a history of bladder cancer.

The test brings rapid detection into the urologist’s office through the use of proteomics technology, the company said in a news release. Four drops of urine are placed on the BladderChek cassette to detect the presence of NMP22, a nuclear matrix protein correlated with bladder cancer.

Clinical trial results reviewed by the FDA showed that NMP22 Bladder-Chek detected 4 times more early-stage bladder tumors and 2.5 times more life-threatening, high-grade tumors than cytology. The test is used in conjunction with cystoscopy.

Recent Videos
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Updated findings from the phase 3 EV-302 trial show enduring responses and survival improvements with enfortumab vedotin plus pembrolizumab.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Related Content